Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Logo for

Science 328 (5979): 749-752

Copyright © 2010 by the American Association for the Advancement of Science

Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21

Jacqueline D. Shields,* Iraklis C. Kourtis,* Alice A. Tomei, Joanna M. Roberts, Melody A. Swartz{dagger}

Abstract: Tumor manipulation of host immunity is important for tumor survival and invasion. Many cancers secrete CCL21, a chemoattractant for various leukocytes and lymphoid tissue inducer cells, which drive lymphoid neogenesis. CCL21 expression by melanoma tumors in mice was associated with an immunotolerant microenvironment, which included the induction of lymphoid-like reticular stromal networks, an altered cytokine milieu, and the recruitment of regulatory leukocyte populations. In contrast, CCL21-deficient tumors induced antigen-specific immunity. CCL21-mediated immune tolerance was dependent on host rather than tumor expression of the CCL21 receptor, CCR7, and could protect distant, coimplanted CCL21-deficient tumors and even nonsyngeneic allografts from rejection. We suggest that by altering the tumor microenvironment, CCL21-secreting tumors shift the host immune response from immunogenic to tolerogenic, which facilitates tumor progression.

Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.

* These authors contributed equally.

{dagger} To whom all correspondence should be addressed. E-mail: melody.swartz{at}epfl.ch


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful.
H.-J. Kim and H. Cantor (2014)
Cancer Immunology 2, 91-98
   Abstract »    Full Text »    PDF »
'There and back again': revisiting the pathophysiological roles of human endogenous retroviruses in the post-genomic era.
G. Magiorkinis, R. Belshaw, and A. Katzourakis (2013)
Phil Trans R Soc B 368, 20120504
   Abstract »    Full Text »    PDF »
Protective Role of the Inflammatory CCR2/CCL2 Chemokine Pathway through Recruitment of Type 1 Cytotoxic {gamma}{delta} T Lymphocytes to Tumor Beds.
T. Lanca, M. F. Costa, N. Goncalves-Sousa, M. Rei, A. R. Grosso, C. Penido, and B. Silva-Santos (2013)
J. Immunol. 190, 6673-6680
   Abstract »    Full Text »    PDF »
Trp53 Inactivation in the Tumor Microenvironment Promotes Tumor Progression by Expanding the Immunosuppressive Lymphoid-like Stromal Network.
G. Guo, L. Marrero, P. Rodriguez, L. Del Valle, A. Ochoa, and Y. Cui (2013)
Cancer Res. 73, 1668-1675
   Abstract »    Full Text »    PDF »
Engineering Approaches to Immunotherapy.
M. A. Swartz, S. Hirosue, and J. A. Hubbell (2012)
Science Translational Medicine 4, 148rv9
   Full Text »    PDF »
Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases.
A. Cipponi, M. Mercier, T. Seremet, J.-F. Baurain, I. Theate, J. van den Oord, M. Stas, T. Boon, P. G. Coulie, and N. van Baren (2012)
Cancer Res. 72, 3997-4007
   Abstract »    Full Text »    PDF »
Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy.
M. A. Swartz, N. Iida, E. W. Roberts, S. Sangaletti, M. H. Wong, F. E. Yull, L. M. Coussens, and Y. A. DeClerck (2012)
Cancer Res. 72, 2473-2480
   Abstract »    Full Text »    PDF »
Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes.
F. Guilloton, G. Caron, C. Menard, C. Pangault, P. Ame-Thomas, J. Dulong, J. De Vos, D. Rossille, C. Henry, T. Lamy, et al. (2012)
Blood 119, 2556-2567
   Abstract »    Full Text »    PDF »
Lymphangiogenesis and Cancer.
A. Christiansen and M. Detmar (2011)
Genes & Cancer 2, 1146-1158
   Abstract »    Full Text »    PDF »
CC chemokine ligand 21 enhances the immunogenicity of the breast cancer cell line MCF-7 upon assistance of TLR2.
S. Wu, X. Lu, Z. L. Zhang, P. Lei, P. Hu, M. Wang, B. Huang, W. Xing, X. T. Jiang, H. J. Liu, et al. (2011)
Carcinogenesis 32, 296-304
   Abstract »    Full Text »    PDF »
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors.
E. D. Thompson, H. L. Enriquez, Y.-X. Fu, and V. H. Engelhard (2010)
J. Exp. Med. 207, 1791-1804
   Abstract »    Full Text »    PDF »
Tumor Immune Evasion.
C. L. Zindl and D. D. Chaplin (2010)
Science 328, 697-698
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882